Michael Gelband’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-244,838
| Closed | -$3.54M | – | 1729 |
|
|
2026
Q1 | $3.54M | Buy |
244,838
+163,370
| +201% | +$2.34M | 0.03% | 551 |
|
|
2025
Q4 | $1.16M | Sell |
81,468
-41,906
| -34% | -$412K | 0.01% | 936 |
|
|
2025
Q3 | $972K | Buy |
+123,374
| New | +$878K | 0.01% | 969 |
|
|
2025
Q2 | – | Sell |
-332,207
| Closed | -$2.71M | – | 1620 |
|
|
2025
Q1 | $2.71M | Buy |
332,207
+53,138
| +19% | +$492K | 0.03% | 594 |
|
|
2024
Q4 | $2.63M | Sell |
279,069
-537,938
| -66% | -$5.59M | 0.02% | 620 |
|
|
2024
Q3 | $8.73M | Buy |
817,007
+35,490
| +5% | +$387K | 0.05% | 260 |
|
|
2024
Q2 | $7.75M | Buy |
781,517
+138,132
| +21% | +$1.42M | 0.05% | 304 |
|
|
2024
Q1 | $7.58M | Buy |
643,385
+271,005
| +73% | +$3.47M | 0.06% | 266 |
|
|
2023
Q4 | $5.28M | Sell |
372,380
-569,053
| -60% | -$6.46M | 0.03% | 330 |
|
|
2023
Q3 | $11.4M | Buy |
941,433
+317,580
| +51% | +$4.1M | 0.11% | 198 |
|
|
2023
Q2 | $7.84M | Buy |
623,853
+468,018
| +300% | +$5.55M | 0.06% | 306 |
|
|
2023
Q1 | $1.73M | Buy |
155,835
+40,044
| +35% | +$494K | 0.01% | 943 |
|
|
2022
Q4 | $1.41M | Sell |
115,791
-177,189
| -60% | -$1.99M | 0.02% | 795 |
|
|
2022
Q3 | $3.06M | Buy |
292,980
+163,746
| +127% | +$1.82M | 0.04% | 584 |
|
|
2022
Q2 | $1.39M | Buy |
+129,234
| New | +$1.06M | 0.02% | 942 |
|
|
2022
Q1 | – | Sell |
-20,758
| Closed | -$240K | – | 2336 |
|
|
2021
Q4 | $240K | Sell |
20,758
-177,013
| -90% | -$1.97M | ﹤0.01% | 1745 |
|
|
2021
Q3 | $1.89M | Buy |
197,771
+109,376
| +124% | +$1.12M | 0.03% | 745 |
|
|
2021
Q2 | $852K | Sell |
88,395
-2,942
| -3% | -$28.7K | 0.01% | 1082 |
|
|
2021
Q1 | $902K | Buy |
91,337
+10,147
| +12% | +$157K | 0.01% | 981 |
|
|
2020
Q4 | $1.88M | Sell |
81,190
-25,326
| -24% | -$518K | 0.02% | 562 |
|
|
2020
Q3 | $1.5M | Buy |
+106,516
| New | +$1.55M | 0.03% | 502 |
|
|
2020
Q1 | – | Sell |
-46,457
| Closed | -$452K | – | 1260 |
|
|
2019
Q4 | $452K | Buy |
46,457
+23,757
| +105% | +$217K | 0.01% | 915 |
|
|
2019
Q3 | $182K | Buy |
+22,700
| New | +$246K | 0.01% | 1149 |
|
Other funds holding FOLD
Michael Gelband's FOLD Position: Q2 2026 in Review
Michael Gelband sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 244,838 shares — an estimated $3.54M sold.
Michael Gelband first reported a position in FOLD in Q3 2019 and held it in 23 quarters. The position peaked at $11.4M in Q3 2023. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Michael Gelband reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Michael Gelband sold 244,838 Amicus Therapeutics shares in Q2 2026, an estimated $3.54M.
- Michael Gelband first reported a position in Amicus Therapeutics in Q3 2019 and held it in 23 quarters.
- Michael Gelband's Amicus Therapeutics position peaked at $11.4M in Q3 2023.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.